Annual report
6523.TEDINET S100OLA5
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 130
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥272.6bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥186.5bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥8.2bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥17.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥5.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥15.5bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥8.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥16.8bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥569.3bn | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥529.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥325.2bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.8bn | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.3bn | at 2020-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥107.0bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥70.3bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥65.3bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥45.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥50.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥36.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥33.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥135.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥7.4bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥95.6bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥19.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥46.61 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥135.84 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥45.22 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥130.45 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥619.38 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥579.44 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 13.3% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 20.1% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 26.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,374 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 9,615 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,368 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.8bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.1bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥6.7bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥24.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | −¥2.1bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥9.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥606m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥18.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥4.2bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥132m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | −¥10.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥137m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥757m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥467.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥432.7bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥408.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥250.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥275.0bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥370.5bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥382.1bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥96.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥50.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥50.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥53.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥50.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥25.1bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-92.71 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.21 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.66 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥355.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥445.36 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥466.02 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 9.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.3% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.4% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,973,941 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,871,099 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,871,099 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 175 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 186 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 175 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 156 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 654 pure |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥18.0bn |
| Diabetes Managementreportable segment | employees | at 2022-03-31 | 2620 pure |
| Diabetes Managementreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥109.4bn |
| Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥109.4bn |
| Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.3bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2022-03-31 | 1958 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥92.2bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥92.2bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥14.1bn |
| Healthcare Solutionsreportable segment | employees | at 2022-03-31 | 4142 pure |
| Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥136.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥136.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥17.0bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥337.9bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥337.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥26.1bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue external | 2020-04-01 → 2021-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥11.4bn |
| Diabetes Managementreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥108.1bn |
| Diabetes Managementreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥108.1bn |
| Diabetes Managementreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥23.9bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥79.9bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥79.9bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥508m |
| Healthcare Solutionsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥116.1bn |
| Healthcare Solutionsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥116.1bn |
| Healthcare Solutionsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥4.5bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥304.1bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥304.1bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥29.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 175 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,993
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row8Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Ascensia Diabetes Care Holdings AG | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | Original text (Japanese)Biolinq Incorpratedが新たな技術を用いて開発しているCGMの将来の販売を企図した事業提携 | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | ― | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Senseonics Holdings, Inc. | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)なお、当社は特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc and internal system to prepare consolidated financial statements etc fairly in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Consolidated statement of financial position IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of profit or loss IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes reporting entity consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes basis of preparation consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting estimates and judgements consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about products and services IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about geographical areas IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about major customers IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes cash and cash equivalents consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes trade receivables consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes inventories consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes other financial assets consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes assets held for sale consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes property plant and equipment consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes goodwill and intangible assets consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes impairment losses consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes investments accounted for using equity method consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes deferred taxes and income taxes consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes trade and other payables consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes borrowings consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes provisions consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |